The main goal of this diploma thesis is to focus on destination management and analyse development potential, turism strategy and suggest further possibilities for tourism development in the Central Bohemia Region. The thesis is devided into theoretical and practical parts. The theoretical part is devoted to the explanation of basic concepts and deals with the topic of destination management. The practical part contents analysis of the Central Bohemia Region, turism strategy and the final evaluation of current situation and development potential of the region.

This Master's Thesis focuses on destination management in Vysočina Region with the accent on cultural tourism aspect. It evaluates the potential of the region and its development by marketing tools and actions of the destination management company. The main method of this evaluation is a market research of the product portfolio in the tourism segment in Vysočina and my own experience from visits to the region. Based on these findings it is then summarized which products are the key ones, which of them are marginal, how it is worked with them, and which products are seen as important and preferential for the future of the destination. The thesis also looks at new forms of cultural tourism, such as diaspora tourism, religious tourism or culinary tourism in the region. Providing the readers with three case studies with SWOT analysis on Bystřicko region, event tourism (Vysočina Arena) and Hospodářský dvůr Bohuslavice it is then evaluated how beneficial their existence is.

由於過去數年間金融業者對於授信品質控管的鬆散，產生國內數量及金額龐大的不良債權，資產管理公司也在此時先後成立，不良資產市場亦因而逐漸熱絡，在整體不動產市場占有一席之地。 從過去文獻可得知影響不動產價格之因素數量眾多，但過去較重視實質屬性對於不動產價格之影響，而較忽略非實質因素對於處分價格的影響，其中有關討論時間因素之研究更為稀少；然而由於不良資產同時包含了一般不動產的特徵屬性（如土地、建物面積及區位）與不良資產專有的特徵屬性（如債務人屬性、處分時間），因此進一步研究影響不良資產處分價格之因素便相對重要。 本研究目的主要在於探討影響不良資產處分時間因素對於不良資產處分價格之影響，以供投資人或公司更重視時間因素對於處分不良資產所產生的成本與效益，作為相關單位評估與處分價格之參考。 因此，本文首先探討影響不良資產處分價格之因素種類，並透過特徵價格法建置不良資產特徵價格模型，並進行實證分析，分析探討時間以及相關因素對於不良資產價格的影響關係與程度。 實證結果顯示處分時間、區位、土地面積、建物面積、利率與債務人屬性對於不良資產處分價格有正向的影響力，唯利率因素雖顯著但與假設不符，本研究認為與投資人之行為與心態有關，或因買方之資金成本隨利率提高而增加。 另特別就處分時間因素而言，實證結果顯示當不良資產處分時間越長，價格越高，因此，應合理延長標的物之市場曝光期，以提高資產的處分價格。雖然延長處分時間，相對機會成本亦增加，但投資人或金融機構應在法務流程上更有彈性，以利不良資產的回收。因此藉由本文之研究成果，希冀提供金融機構或資產管理公司處分不良資產時，應謹慎考量處分時間與處分價格間的得失權宜，擬定最適處分策略。 / Due to the loosening credit in the past few years, Taiwan’s non-performing loans, both in terms of volume and amount, burgeoned, resulting in rapid growth of establishments of asset management companies. NPLs consequently became one asset class that was highly sought after in the overall real estate market in Taiwan. From past literatures we understand that there are various factors affecting real estate prices. However, most studies focused on the physical attributes of the underlying real estate, rather than non-physical attributes’ effect on real estate prices. Even more rare are studies that focus on the impact of time. Since non-performing loans encompass both performing real estates’ attributes (land and building area, and location) and non-performing real estates’ attributes (characteristics of debtors and days on market), further study on such factors that affect the real estate prices should be warranted. This paper is to probe the effects of days on market on non-performing loans’ prices. This paper should help investors (including asset management companies) understand the importance of time in regards to its effect on the cost and benefits when disposing NPLs. Therefore, this paper first explores the different factors that affect the prices of NPLs by using Hedonic price method to build models to determine the prices, and then uses real examples to analyze the relationship and magnitude of time and other factors’ impact on NPLs’ prices. Empirical data suggests that days on market, location, land area, building area, interest rate, and borrower types all have positive impact on the prices of NPLs. Interest rate, although showed positive relationship, did not fit the hypothesis, which is probably due to investors’ behavior or mindset or increase in cost of funding as interest rate rises. Specifically for days on market, empirical results manifest that the longer the time on market, the higher the resolution price is. Therefore, it is recommended to reasonably lengthen the days on market to achieve higher resolution price. Although the increase in days on market will increase the opportunity cost, investors and financial institutions should be able to enjoy more flexibility in the legal process, thereby resulting in better recovery. Finally, through the research of this paper, financial institutions and AMCs should carefully consider the cost/benefit between time on market and resolution prices to achieve optimal resolution strategy.

This work deals with intercultural management in Europian Union, that brings many pro-blems in company's management. Based on self-learning organization concept, this work aims to explain, that an organization can not even succesfully overcome these problems but can even make a comparative advantage from them. Supporting with results from analysis of middle-europian unit of company KONE.

The main goal of this thesis is to describe and analyse methods, which were used by countries affected by the Asian financial crisis to resolve related problems and also analyse how these solutions affected public debt. For this purpose I chose three Asian countries, Thailand, Indonesia and South Korea. These countries have one in common, their governments decided to establish Asset Management company to resolve problems of bank sector. This thesis describes how they were successful in their aspirations and fallout of financial crises on choosen countries.

The thesis covers a proposal of extention of portfolio of services of GRANTECH limited liability company. It is divided into three parts. The first one is based on theoretical starting points. It describes in details some chosen methods which explore inside and outside surroundings of the company. In the second part of the thesis, it means in the analytical part, these methods apply to the company itself. The third part contains suggestions of extension of services portfolio which will lead to an increase of competitive ability. The thesis represents a document which will help the company owner to realise the suggested changes.

Presented dissertation is involved in the knowledge management in high-tech companies in the Czech Republic. The work with knowledge influences all areas in the company. Evaluation of formulated strategy and arrangement of development of conditions, resulting in future sustainability, are essential in the context of business success. The topic aims at organized use of knowledge in the company management activities; the emphasis is put on key factors of knowledge management. The primary objective of said dissertation thesis has been the elaboration of methodology of incorporation of elements of knowledge management into the management activities within the framework of business concept in the Czech high-tech sector. Partial objectives have been determined in closed link. Definition of objectives of the dissertation and individual hypotheses has been based on secondary research. On the basis of primary research, combining both qualitative and quantitative methods, partial conclusions have been outlined. Results of a case study and small group discussion have been applied for questionnaire investigation, supported also by theoretical knowledge. Recommendation, resulting in the proposal of methodology, has been framed after the summarization of partial conclusions of the individual research approaches. Moreover, stress has been placed to a schematic visualization. Finally, presented dissertation at its end presents its contributions in the area of science and research, practice, pedagogy and methodology.

Background: Warfarin is an anticoagulant that is used for the prophylactic and therapeutic treatment for a wide range of thrombo-embolic disorders. The prescribing and monitoring of warfarin therapy is challenging due to the fact that warfarin exhibits numerous interactions with other drugs and a variety of factors that influence the dosing of warfarin. Objective: The general objective of this study was to investigate the prevalence of drugs prescribed with warfarin that may have a potential drug-drug interaction (DDI) with warfarin. Methods: This was a cross-sectional, observational or qualitative study that was conducted on medicine claims data of a pharmaceutical benefit management company for patients receiving warfarin therapy for a six year period, ranging from 1 January 2005 to 31 December 2010. Drug products that were co-prescribed with warfarin were also identified from the medicine claims database. The total number of prescriptions for all drug products during the study period were analysed and compared to the warfarin dataset. This was done by means of the SAS 9.1® computer package (SAS Institute, 2004). The total number of prescriptions and medicine items claimed from the database during the study period were respectively 49 523 818 and 118 305 941. Potential DDls between warfarin and coprescribed drugs were identified and classified according to a clinically significant rating. The clinically significance ratings of potential DDls are described in three degrees of severity, identified as major, moderate and minor (Tatro, 2011 :xiv). Results: The database consisted of 427 238 warfarin prescriptions and 427 744 warfarin medicine items, which represented 0.9% of the total number of prescriptions and 0.4% of total number of medicine items. The total number of patients who claimed warfarin prescriptions through the database represented 0.9% (n=68 575) of the total number of patients who claimed prescriptions in the total database (2005-2010). General practitioners prescribed the highest frequency of warfarin medicine items, representing 58.3% (n=249 202) of the total number prescribed. The age group that claimed the highest frequency of warfarin prescriptions (n=327 592, 76.6%) and the highest frequency of warfarin medicine items (n=327 984, 76.7%) was age group 4 (consisting of patients 59 years and older). The distribution between females and males regarding warfarin prescriptions claimed (n=205 999, 48.2%; n=221 117, 51.8%) and warfarin medicine items claimed (n=206 232, 48.2%; n=221 390, 51.8%) were almost equal. General practitioners prescribed the highest average PDD (7.01 mg ± 9.86 mg) of warfarin medicine items. Paediatric cardiologists prescribed the lowest average PDD (4.61 mg ± 1.29 mg) of warfarin medicine items. A d-value of 0.1 indicates that there is no practical difference of the average PDD between general practitioners and paediatric cardiologists. The average PDD of warfarin medicine items between females (6.60 mg ± 9.06 mg) and males (6.74 mg± 8.41 mg) was almost equal. The age group who was prescribed the highest average PDD was age group 2 (consisting of patients 20 years to 39 years old) (7.42 mg± 7.42 mg). Age group 4 (consisting of patients 59 years and older) (6.50 mg± 8.90 mg) was prescribed the lowest average PDD of warfarin medicine items. A d-value of 0.1 indicates that there is no practical difference of the average PDDs of warfarin medicine items between these two age groups. The results revealed that drugs with a significance rating (SR) of 1 (n=155 066, 43.3%), 2 (n=30128, 8.4%), 4 (n=137144, 38.3%), and 5 (n=36144, 10.1%) were co-prescribed with warfarin in the six year study period. The five drugs that was co-prescribed with warfarin most frequently was aspirin (n=48 903, 13.6%), thyroxine (n=33 954, 9.5%), amiodarone (n=25 056, 7.0%), simvastatin (n=19 070, 5.3%) and celecoxib (n=10 794, 3.0%). These five drugs have a SR of 1. Conclusions: This study showed that the top five drugs most frequently prescribed with warfarin are aspirin, thyroxine, amiodarone, simvastatin and celecoxib. These drugs can potentially interact with warfarin. The potential interactions of these drugs are rated with a significance rating of 1. This concludes that drugs that can potentially cause life threatening effects and permanent damage are commonly co-prescribed with warfarin. Clinical data concerning the INR or PT must be obtained in order to evaluate whether or not warfarin therapy is changed when a potentially interacting drug is co-prescribed. The age of the patients as well as the duration of warfarin treatment should also be obtained in order to assess whether warfarin treatment is changed with the progression of age. / MPharm (Pharmacy Practice), North-West University, Potchefstroom Campus, 2013

Background: Warfarin is an anticoagulant that is used for the prophylactic and therapeutic treatment for a wide range of thrombo-embolic disorders. The prescribing and monitoring of warfarin therapy is challenging due to the fact that warfarin exhibits numerous interactions with other drugs and a variety of factors that influence the dosing of warfarin. Objective: The general objective of this study was to investigate the prevalence of drugs prescribed with warfarin that may have a potential drug-drug interaction (DDI) with warfarin. Methods: This was a cross-sectional, observational or qualitative study that was conducted on medicine claims data of a pharmaceutical benefit management company for patients receiving warfarin therapy for a six year period, ranging from 1 January 2005 to 31 December 2010. Drug products that were co-prescribed with warfarin were also identified from the medicine claims database. The total number of prescriptions for all drug products during the study period were analysed and compared to the warfarin dataset. This was done by means of the SAS 9.1® computer package (SAS Institute, 2004). The total number of prescriptions and medicine items claimed from the database during the study period were respectively 49 523 818 and 118 305 941. Potential DDls between warfarin and coprescribed drugs were identified and classified according to a clinically significant rating. The clinically significance ratings of potential DDls are described in three degrees of severity, identified as major, moderate and minor (Tatro, 2011 :xiv). Results: The database consisted of 427 238 warfarin prescriptions and 427 744 warfarin medicine items, which represented 0.9% of the total number of prescriptions and 0.4% of total number of medicine items. The total number of patients who claimed warfarin prescriptions through the database represented 0.9% (n=68 575) of the total number of patients who claimed prescriptions in the total database (2005-2010). General practitioners prescribed the highest frequency of warfarin medicine items, representing 58.3% (n=249 202) of the total number prescribed. The age group that claimed the highest frequency of warfarin prescriptions (n=327 592, 76.6%) and the highest frequency of warfarin medicine items (n=327 984, 76.7%) was age group 4 (consisting of patients 59 years and older). The distribution between females and males regarding warfarin prescriptions claimed (n=205 999, 48.2%; n=221 117, 51.8%) and warfarin medicine items claimed (n=206 232, 48.2%; n=221 390, 51.8%) were almost equal. General practitioners prescribed the highest average PDD (7.01 mg ± 9.86 mg) of warfarin medicine items. Paediatric cardiologists prescribed the lowest average PDD (4.61 mg ± 1.29 mg) of warfarin medicine items. A d-value of 0.1 indicates that there is no practical difference of the average PDD between general practitioners and paediatric cardiologists. The average PDD of warfarin medicine items between females (6.60 mg ± 9.06 mg) and males (6.74 mg± 8.41 mg) was almost equal. The age group who was prescribed the highest average PDD was age group 2 (consisting of patients 20 years to 39 years old) (7.42 mg± 7.42 mg). Age group 4 (consisting of patients 59 years and older) (6.50 mg± 8.90 mg) was prescribed the lowest average PDD of warfarin medicine items. A d-value of 0.1 indicates that there is no practical difference of the average PDDs of warfarin medicine items between these two age groups. The results revealed that drugs with a significance rating (SR) of 1 (n=155 066, 43.3%), 2 (n=30128, 8.4%), 4 (n=137144, 38.3%), and 5 (n=36144, 10.1%) were co-prescribed with warfarin in the six year study period. The five drugs that was co-prescribed with warfarin most frequently was aspirin (n=48 903, 13.6%), thyroxine (n=33 954, 9.5%), amiodarone (n=25 056, 7.0%), simvastatin (n=19 070, 5.3%) and celecoxib (n=10 794, 3.0%). These five drugs have a SR of 1. Conclusions: This study showed that the top five drugs most frequently prescribed with warfarin are aspirin, thyroxine, amiodarone, simvastatin and celecoxib. These drugs can potentially interact with warfarin. The potential interactions of these drugs are rated with a significance rating of 1. This concludes that drugs that can potentially cause life threatening effects and permanent damage are commonly co-prescribed with warfarin. Clinical data concerning the INR or PT must be obtained in order to evaluate whether or not warfarin therapy is changed when a potentially interacting drug is co-prescribed. The age of the patients as well as the duration of warfarin treatment should also be obtained in order to assess whether warfarin treatment is changed with the progression of age. / MPharm (Pharmacy Practice), North-West University, Potchefstroom Campus, 2013

Collective investments have become a very popular investment vehicle in South Africa because it is, among other things, transparent, liquid and easily accessible. Growing investor knowledge, good market returns and its suitability for diversification, which minimizes risk, also contributes to its popularity. A value chain that adds value to the investor has developed around the collective investment scheme. The role players in this chain include the investment manager, the management company and financial intermediaries. The growth in this part of the collective investment industry has been so dynamic that regulation and the introduction of various new intermediary layers are constantly affecting the value chain and the value added for the investor. Research was conducted to assess the impact of the value chain on the behaviour of the individual investor and the effect this has on wealth creation. The literary review established that the environment surrounding this dynamic and interdependent value chain is well-regulated and that costs and investor behaviour could have a significant impact on investment returns. The empirical study revealed that the average individual investor recognizes the impact of the value chain on his investment, but perceives himself as being knowledgeable enough to avert ineffectiveness in the chain by ensuring desired investment returns through good investment decisions. Over-diversification and irresponsible switching between funds by the investor can, however, destroy value and negate the effect of long-term returns. / Business Management / M. Com. (Business Management)